Upadacitinib APIs by Loncom Pharma represent a new generation of Janus kinase inhibitors, providing relief for autoimmune conditions such as rheumatoid arthritis. These APIs offer a new hope for patients with moderate to severe cases, where other treatments may not have been effective.
